| 8.2 -0.22 (-2.61%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.29 | 1-year : | 13.48 |
| Resists | First : | 9.67 | Second : | 11.54 |
| Pivot price | 8.68  |
|||
| Supports | First : | 6.65 | Second : | 5.53 |
| MAs | MA(5) : | 8.6 |
MA(20) : | 9.18 |
| MA(100) : | 6.7  |
MA(250) : | 6.15 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.2 |
D(3) : | 45.3 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 13.51 | Low : | 2.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OLMA ] has closed above bottom band by 31.8%. Bollinger Bands are 21.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.85 - 8.91 | 8.91 - 8.96 |
| Low: | 7.95 - 8 | 8 - 8.05 |
| Close: | 8.12 - 8.21 | 8.21 - 8.28 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Tue, 04 Nov 2025
Olema Oncology (NASDAQ: OLMA) Grants Inducement Options for 148,600 Shares - Stock Titan
Mon, 03 Nov 2025
Olema (NASDAQ: OLMA) to participate in Guggenheim, UBS and Jefferies conferences - Stock Titan
Sun, 02 Nov 2025
Pier Capital LLC Has $3.29 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Sat, 01 Nov 2025
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up - Here's Why - MarketBeat
Thu, 30 Oct 2025
Olema Pharmaceuticals to Present Phase 3 OPERA-02 Trial Details at SABCS 2025 - Quiver Quantitative
Thu, 30 Oct 2025
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 7,550 (K) |
| Shares Short P.Month | 8,240 (K) |
| EPS | -1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -49.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -127 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -4.17 |
| PEG Ratio | 0 |
| Price to Book value | 1.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|